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Abstract
Background: Chronic psychological stress is associated with increased intestinal epi‐
thelial permeability and visceral hyperalgesia. Lubiprostone, an agonist for chloride 
channel‐2, promotes secretion and accelerates restoration of injury‐induced epithe‐
lial barrier dysfunction. The mechanisms underlying how lubiprostone regulates 
colon epithelial barrier function and visceral hyperalgesia in chronic stress remain 
unknown.
Methods: Male rats were subjected to water avoidance stress for 10 consecutive days. 
Lubiprostone was administered daily during the stress phase. Visceromotor response 
to colorectal distension was measured. Human colon crypts and cell lines were treated 
with cortisol and lubiprostone. The transepithelial electrical resistance and FITC‐dex‐
tran permeability were assayed. Chromatin immunoprecipitation was conducted to 
assess glucocorticoid receptor binding at tight junction gene promoters.
Key Results: Lubiprostone significantly decreased chronic stress‐induced visceral hy‐
peralgesia in the rat (P	<	0.05;	n	=	6).	WA	stress	decreased	occludin	and	claudin‐1	and	
increased claudin‐2 in rat colon crypts, which was prevented by lubiprostone. Cortisol 
treatment induced similar alterations of tight junction protein expression in Caco‐2/
BBE cells (P < 0.05) and significantly changed paracellular permeability in monolayers 
(P < 0.01). These changes were blocked by lubiprostone. Glucocorticoid receptor and 
its binding at occludin promoter region were decreased in cortisol‐treated cells and 
human colon crypts, which was largely reversed by lubiprostone. In rat colonic cells, 
glucocorticoid receptor and its co‐chaperone proteins were down‐regulated after 
corticosterone treatment and lubiprostone reversed these changes.
Conclusions & Inferences: Lubiprostone preferentially prevents chronic stress‐in‐
duced alterations of intestinal epithelial tight junctions, barrier function, and visceral 
hyperalgesia that was associated with modulation of glucocorticoid receptor expres‐
sion and function.
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1  | INTRODUC TION
Irritable bowel syndrome (IBS) is a common functional gastrointes‐
tinal	 disorder	 characterized	 by	 abdominal	 discomfort	 or	 pain	 and	
changes in bowel habit.1‐3 Increasing evidence suggests that dis‐
turbance of the intestinal epithelial barrier function contributes to 
diarrhea‐prone IBS‐related symptoms.4,5 For example, the enhanced 
paracellular permeability is positively correlated with abdominal 
pain in IBS patients.6 Recently, enhanced stress effects on gut bar‐
rier function have been implicated as a potential mechanism contrib‐
uting to the pathophysiology of IBS.7,8 Chronic stress has significant 
effects on gut physiology and pathophysiology including alterations 
in gastrointestinal motility, enhanced visceral pain perception (hy‐
peralgesia), and impaired intestinal barrier function in animal mod‐
els9,10 and IBS patients.11,12
The corticoid receptor is one of the major players in mediat‐
ing many physiological events in response to acute and chronic 
stress.13,14 The glucocorticoid receptor (GR), a ligand‐activated 
transcription factor, depends on molecular chaperones for in vivo 
function.15	After	 ligand	binding,	GR	 is	 translocated	 to	 the	nucleus	
and	 binds	 to	 DNA	 on	 glucocorticoid	 response	 elements	 (GREs),	
recruiting transcriptional machinery and various coactivators and 
corepressors to positively or negatively regulate gene transcription. 
GR translocation is mediated by the co‐chaperone protein FK506 
binding protein 5 (FKBP5) which is associated with the chaperone 
heat‐shock protein 90 (Hsp90) to form a chaperon complex.16,17 
The	Hsp90‐GR	complex,	in	its	ATP‐bound	form,	is	stabilized	by	co‐ 
chaperone p23, whereas heat‐shock protein 70 (Hsp70) mediates GR 
complex assembly and activity.15,18 The importance of these chaper‐
ones has been established in the pathogenesis and therapy of stress 
and mental disorders.14,17,19 In human colon epithelial cells, induction 
of Hsp70 expression displays a protective role in the epithelial bar‐
rier integrity which results in a decrease in paracellular permeabil‐
ity.20 The augmentation of heat‐shock proteins and reduced barrier 
integrity has been reported in colon tissues in an acute stress animal 
model.21 The mechanism underlying how GR and its chaperones 
regulate intestinal paracellular permeability in chronic stress has not 
been determined.
Lubiprostone, a bicyclic fatty acid derived from prostaglandin E1 
(PGE1), activates chloride channel type 2 (CIC‐2) in the apical mem‐
brane of epithelial cells22 and promotes the passage of water into the 
luminal space and bowel movements which can improve symptoms 
associated with constipation.23,24 CIC‐2 channel plays an import‐
ant role in the modulation of tight junctions by influencing caveolar 
trafficking of the tight junction protein occludin.25 Targeted activa‐
tion of CIC‐2 chloride channels with lubiprostone stimulates repair 
of intestinal barrier function in the ischemia‐injured porcine ileum 
and colon which is associated with impaired expression and func‐
tion of tight junction proteins resulting in increased permeability.26 
However, it is unknown whether lubiprostone has a preventative 
effect on the increased permeability and enhanced visceral pain in 
animal models of chronic stress. The goal of the present study was 
to examine the hypothesis that lubiprostone prevents GR‐mediated 
disruption of colon epithelial tight junction proteins and prevents in‐
crease of paracellular permeability and visceral pain.
2  | MATERIAL S AND METHODS
2.1 | Animals and water avoidance (WA) stress
Male	Sprague‐Dawley	rats	(weighing	160‐180	g)	were	obtained	from	
Charles	 River	 Laboratories	 (Wilmington,	MA,	 USA).	 Animals	 were	
housed in the animal facility that was maintained at 22°C with an 
automatic 12‐hours light/dark cycle. The animals received a stand‐
ard	laboratory	diet	and	tap	water	ad	libitum.	All	experiments	were	
approved by the University of Michigan Committee on Use and Care 
of	Animals	according	to	National	Institutes	of	Health	guidelines.
The animal study was conducted as shown in the following exper‐
imental scheme. Briefly, young‐adult male rats were adapted in the 
animal facility for 3‐5 days and then randomly grouped and subjected 
to	10‐day	WA	stress	as	described	previously.27 The rats were placed 
on a glass platform in the middle of a tank filled with water (22°C) to 
1 cm below the height of the platform. The animals were maintained 
on	the	tank	for	1	hour	in	the	morning	(8	AM–10	AM)	daily	for	10	con‐
secutive	days.	Lubiprostone	(Takeda	Pharmaceutical	North	America,	
Deerfield,	IL,	USA)	was	delivered	orally	instead	of	gavage	to	rats,	to	
K E Y W O R D S
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lubiprostone, tight junction
Key Points
• Chronic stress is associated with increased intestinal 
epithelial permeability and visceral hyperalgesia. 
Lubiprostone accelerates intestinal epithelial repair. It is 
unknown how lubiprostone regulates colon epithelial 
barrier function and visceral pain in chronic stress.
• Lubiprostone prevented chronic stress‐induced differ‐
ential alterations of epithelial tight junction proteins, 
down‐regulation of glucocorticoid receptor and its 
chaperones, and increase in paracellular permeability 
and visceral pain in the rodent and human.
• Our findings support a novel mechanism for lubipros‐
tone to regulate intestinal permeability and visceral 
pain.
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avoid distress or irritation, twice daily with 500 μL medium‐chain tri‐
glycerides (MCT) as described.28	A	dose	of	10	μg/kg body weight was 
suggested by the manufacturer and proved effective by a serial dose 
response pre‐experiments. Rats were weighed each day for deter‐
mination	of	the	amount	of	 lubiprostone	delivered.	All	animals	were	
treated with lubiprostone prior to stress procedure each day for a 
period	of	10	days	during	the	WA	stress	phase	(WA+Lub	group).	MCT,	
the delivery medium for lubiprostone, was administrated similarly to 
the	SHAM	control	(MCT‐CT)	rats	and	WA	stress	(MCT‐WA)	rats.	The	
MCT‐CT rats were placed similarly for 1 hour daily for 10 days in a 
tank without water. The number of fecal output was recorded daily 
for	each	rat	after	1	hour	WA	or	SHAM	stress.	Behavioral	assessments	
were conducted on the next day after completing the 10‐day stress 
procedure. Separate groups of animals without behavioral measure‐
ments were used to harvest colon crypts from the distal colon, the 
same segment for balloon distention and visceral pain measurement. 
The aliquots of isolated colon crypts were used for biochemical and 
molecular	characterization.	The	experimenter	was	blinded	to	animal	
treatment during behavioral experiments.
2.2 | Visceral motor response (VMR) to colorectal 
distention (CRD)
Visceral pain measurement was conducted as previously de‐
scribed.27,29	 Briefly,	 rats	 were	 deeply	 anesthetized	 with	 subcuta‐
neous	 injection	 of	 a	mixture	 of	 ketamine	 (60	mg/kg)	 and	 xylazine	
(5	mg/kg).	An	incision	was	made	in	the	skin	of	the	lower	abdomen,	
and two perfluoroalkoxy‐coated, 32‐gauge stainless steel wires 
were inserted into the external oblique pelvic muscles superior to 
the	 inguinal	 ligament.	Animals	were	 injected	with	500	µL	of	 0.9%	
saline, and artificial tears eye ointment was placed onto their eyes. 
The animals were then allowed to recover for 3‐5 days prior to the 
VMR measurement.
Measurement of the VMR to CRD was conducted in awake ani‐
mals	on	day	11,	next	day	after	the	completion	of	10‐day	WA	stress	
procedure. The VMR was quantified by measuring activity of elec‐
tromyography (EMG) in the external oblique musculature in the 
awake animals. CRD was conducted to constant pressures of 10, 
20, 40, and 60 mm Hg by a custom‐made distension control device. 
The	responses	were	considered	stable	if	there	was	<20%	variability	
between 2 consecutive trials of CRD at 60 mm Hg. The increase in 
the	area	under	curve	 (AUC),	which	 is	 the	sum	of	all	 recorded	data	
points multiplied by the sample interval (in seconds) after baseline 
subtraction, was presented as the overall response during the course 
of the CRD test.
2.3 | Cell culture and treatment
The Caco‐2/BBE colonic epithelial cell line, originally derived 
from a human adenocarcinoma, was obtained from Prof. David E 
Smith	 (University	 of	 Michigan,	 Ann	 Arbor,	 MI,	 USA).	 Cells	 were	
maintained	 at	 50%	 density	 in	 DMEM	 containing	 25	mmol/L	 glu‐
cose, 3.7 g/L NaHCO3, 4 mmol/L l‐glutamine,	 1%	 nonessential	
amino acids, 100 U/L penicillin/streptomycin (complete medium), 
supplemented	 with	 10%	 heat‐inactivated	 FBS	 (Sigma‐Aldrich,	 St	
Louis,	MO,	USA)	at	37°C	in	10%	CO2. For differentiation, cells were 
seeded on Transwell filters, 12 mm diameter, 0.4 μm pore diameter 
(Corning	Inc,	Lowell,	MA,	USA)	at	a	density	of	3.5	×	105 cells/cm2 
in complete medium for two days to allow the formation of a con‐
fluent cell monolayer. From day 3 after seeding, cells were kept in 
the	same	medium	in	both	compartments	(10%	FBS	Symmetric)	and	
allowed to differentiate for 21 days with regular medium changes 
three times a week.30
Rat colon epithelial FRC/TEX cell lines used in this study was 
a generous gift from Dr Kimberly Rieger‐Christ, Sophia Gordon 
Cancer	 Center,	 Burlington,	MA.	 These	 cells	 consist	 of	 two	myco‐
plasma‐negative rat colonic epithelial cell lines and the immortal‐
ized	 non‐tumorigenic	 cell	 line.31 The derivative transformed FRC/
TEX cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM)	supplemented	with	10%	fetal	bovine	serum	 (FBS),	hydro‐
cortisone	 (0.02	µg/mL),	 insulin	 (0.25	µg/mL),	 transferrin	 (0.12	µg/
mL),	glucose	(67.5	µg/mL),	and	penicillin‐streptomycin	(50	U/mL)	in	
a	 humidified	 environment	 at	 37°C	 in	 the	 presence	 of	 10%	CO2.
32 
For treatment, FRC/TEX and Caco‐2/BBE Cells were incubated with 
GR agonist corticosterone (500 nmol/L) for 24 hours with/without 
lubiprostone (100 nmol/L; dissolved in DMSO). DMSO at the final 
0.01%	(v/v)	concentration	was	used	as	the	vehicle	control.	The	cor‐
tisol dose at 500 nM was determined to mimic the serum level in 
the	stressed	rats	after	10‐day	chronic	WA	stress	as	described	pre‐
viously.9 Treated cells were then harvested for immunofluorescence 
staining and Western blot analysis.
2.4 | Human colon crypts culture and treatment
Human colon crypts culture was conducted as described previously.33 
Briefly, colon biopsies were collected from healthy control patients 
in cold Dulbecco’s minimal essential medium (Life Technologies, 
Carlsbad,	 CA,	 USA),	 supplemented	with	 2	mmol/L	 GlutaMax	 (Life	
Technologies),	50	µg/mL	gentamicin	(Life	Technologies),	100	µg/mL	
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normocin	(InvivoGen,	San	Diego,	CA,	USA),	and	2.5	µg/mL	ampho‐
tericin (Life Technologies) at the University of Michigan Hospitals 
according to the procedures approved by the Institutional Review 
Board (IRB). The mucosa/submucosa was surgically separated from 
the muscularis propria and incubated in Dulbecco’s phosphate‐buff‐
ered saline (DPBS; Life Technologies) supplemented with the above 
antimicrobials for 15 minutes. The tissues were then incubated in 
10	mmol/L	 dithiothreitol	 (DTT;	 Sigma‐Aldrich)	 for	 15	minutes,	 fol‐
lowed	by	treatment	with	8	mmol/L	ethylenediaminetetraacetic	acid	
(EDTA;	 Sigma‐Aldrich)	 for	 75	minutes.	 Crypts	 were	 isolated	 and	
washed with cold keratinocyte growth medium gold (KGMG) and 
cultured	in	KGMG	with	Matrigel	(BD	Biosciences,	San	Jose,	CA,	USA)	
at	a	crypt	density	of	50‐75	crypts/50	µL	Matrigel/2	cm2	well.	After	
cultured for 3 hours, crypts were treated with cortisol (500 nmol/L) 
with/without	lubiprostone	(100	nmol/L)	for	24	hours.	DMSO	(0.01%	
v/v) was used as the vehicle control.
2.5 | Measurement of transepithelial electrical 
resistance (TEER) and FITC‐Dextran permeability
The TEER assay was used to measure the effect of treatments on the 
integrity of the tight junctions between Caco‐2/BBE cells as a model 
of human intestinal epithelium. Caco‐2/BBE cells were seeded on 24‐
well	12‐mm	polyester	Transwell	filters	(Corning,	Corning,	NY,	USA)	
with 0.4 μm	pore	size	at	a	concentration	of	2	×	105 cells/Transwell. 
Cells were grown in DMEM supplemented with 0.01 mg/mL human 
transferrin,	10%	FBS,	and	pen/strep	for	21	days	until	they	formed	a	
differentiated monolayer. For treatment, cortisol (500 nmol/L) was 
added to the apical site (upper chamber) of the transwell cultures 
since the expression of GR receptors is dominant at the apical epi‐
thelial cells in human colon crypts.34 To determine the effect of cor‐
tisol, the TEER was measured before and after cortisol treatment 
for 24 hours in the presence and absence of lubiprostone (100 nm; 
inner/upper	chamber)	or	DMSO	(0.01%	v/v)	vehicle	using	an	EVOM2	
epithelial voltage meter (World Precision Instruments, Sarasota, FL, 
USA).	After	washing	the	cells,	DMEM	was	dispensed	 into	each	fil‐
ter in the apical and basolateral chamber; electrical probes were 
then immersed in the apical and basolateral chambers to measure 
the resistance of the monolayer. TEER was calculated after subtrac‐
tion of the intrinsic resistance of the cell‐free filter. To measure dex‐
tran permeability, fluorescein isothiocyanate (FITC)‐dextran (4 kDa; 
3 mg/mL) was added to the upper chamber without medium change. 
Aliquots	were	withdrawn	from	the	lower	chambers	after	4	hours	and	
assayed for fluorescence at 515 nm with excitation at 492 nm.
2.6 | Western blot analysis
Colon tissues in rats that had not undergone surgery or visceral pain 
measurement were dissected out next day after completing the 
10‐day	WA	stress	procedure.	The	dissected	colon	segments	were	
reversed inside‐out and washed with 2 mmol/L DTT in cold PBS. 
Then,	tissues	were	incubated	with	4	mmol/L	EDTA	in	cold	PBS	for	
5 minutes with shaking. The epithelium layers were gently scrapped 
off with a forceps and collected in PBS, followed by centrifugation 
at 500 g for 5 minutes. The crypts aliquots containing epithelium 
were	stored	at	−80°C	for	later	use	or	immediately	homogenized	in	
ice‐cold	lysis	buffer	containing	50	mmol/L	Tris,	pH	8.0,	150	mmol/L	
NaCl,	 1	mmol/L	 EGTA,	 50	mmol/L	 NaF,	 1.5	mmol/L	 MgCl2,	 10%	
v/v	glycerol,	1%	v/v	Triton	X‐100,	1	mmol/L	phenylmethylsulfonyl	
fluoride, 1 mmol/L Na3VO4, and Complete Protease Inhibitor cock‐
tail	 (Roche	 Diagnostics,	 Indianapolis,	 IN,	 USA).	 In	 separate	 stud‐
ies, rat FRC/TEX and human Caco‐2/BBE cells were collected and 
homogenized	using	the	same	lysis	buffer.	Proteins	were	separated	
and transblotted to polyvinylidene difluoride membranes (Bio‐Rad, 
Hercules,	CA,	USA).	The	membranes	were	blocked	and	 incubated	
with	primary	antibodies	for	GR	(Cell	Signaling,	Danvers,	MA,	USA),	
mineralocorticoid	 receptor	 (MR;	Santa	Cruz	Biotechnology,	 Santa	
Cruz,	 CA,	 USA),	 FKPB5	 (Cell	 Signaling),	 Hsp90	 (Cell	 Signaling);	
Hsp70	 (Cayman	 Chemical,	 Ann	 Arbor,	 MI,	 USA),	 Hsp23	 (p23;	
Cayman Chemical), claudin‐1 & claudin‐2 (Invitrogen Corp., 
Camarillo,	CA,	USA),	occludin	 (Abcam,	Cambridge,	MA,	USA),	and	
‐actin	(Sigma‐Aldrich)	at	4°C,	overnight,	and	subsequently	with	sec‐
ondary antibodies (1:5000; Cell Signaling) for 1 hour at room tem‐
perature. The X‐ray films were developed using SuperSignal West 
Dura Chemiluminescent Substrate Kit (Thermo Fisher Scientific, 
Rockford,	IL,	USA).
2.7 | Quantitative PCR (qPCR)
Total	 RNA	 from	 rat	 colon	 crypt	 aliquots	 was	 isolated	 using	 the	
Trizol	 (Life	 Technologies,	 Grand	 Island,	 NY,	 USA)	 and	 RNeasy	 kit	
(Qiagen, Hilden, Germany). qPCR was performed using the Bio‐
Rad iScript One‐Step Reverse‐Transcription PCR Kit with SYBR 
Green	 (Bio‐Rad,	 Hercules,	 CA,	 USA)	 using	 the	 following	 specific	
primers	 from	 Integrated	 DNA	 Technologies	 (Coralville,	 IA,	 USA):	
claudin‐1:	 forward‐ATGACCCCTATCAATGCCAG,	 reverse‐TGGTG 
TTGGGTAAGAGGTTG;	 claudin‐2:	 forward‐CAGCTCCGTTTTCTA 
GATGCC,	reverse‐TGCGGCTCTTGTTTCTTGGA;	occludin:	forward‐ 
AAAGCAGGGAAGGCGAAG,	reverse‐TGTTGATCTGAAGTGATAGG 
TGG;	 GR:	 forward‐GCGTCAAGTGATTGCAGCAGTGAA,	 reverse‐ 
GCAAAGCAGAGCAGGTTTCCACTT;	GAPDH:	forward‐TGTGAACG 
GATTTGGCCGTA,	reverse‐TGAACTTGCCGTGGGTAGAG.
2.8 | Chromatin Immunoprecipitation (ChIP)
Chromatin immunoprecipitation was performed using a chromatin im‐
munoprecipitation	kit	(EMD	Millipore,	Billerica,	MA,	USA).	Briefly,	the	
colon	crypt	aliquots	or	Caco‐2/BBE	cells	were	cross‐linked	using	1%	
formaldehyde and terminated by incubation with 0.125 mol/L glycine 
for 5 minutes. The cell lysate was incubated for 10 minutes at 4°C, and 
the	crude	nuclear	extract	was	collected	by	centrifugation	at	600	×	g for 
5	minutes	at	4°C.	The	DNA	was	sonicated	to	random	fragments	between	
200 bp and 500 bp. The chromatin was subjected to immunoprecipita‐
tion using the following antibodies: GR (#3660; Cell Signaling Technology, 
Danvers,	MA,	USA).	Normal	rabbit	IgG	was	used	as	the	control.	DNA	
was eluted in elution buffer and used for PCR amplification. Primers 
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for	 rat	 occludin	 promoter	 (forward‐CATTTAATCAAACCTGGCAGC,	
reverse‐CCTGGAGCTAGCAGAGTTAAAAGG)	 and	 for	 human	 oc‐
cludin	 promoter	 (forward‐CGACACACCACACCTACACT,	 reverse‐
ATGCGCACCAACGTGGAA)	 were	 obtained	 from	 Life	 Technologies	
(Grand	 Island,	NY,	USA).	PCR	was	performed	using	Bio‐Rad	 iScript™	
One‐Step	RT‐PCR	Kit	with	SYBR®	Green	(Bio‐Rad,	Hercules,	CA,	USA).
2.9 | Immunofluorescence
FRC/TEX cells cultured on cover glasses were fixed for 30 minutes 
in	4%	paraformaldehyde	 in	0.1	mol/L	phosphate	buffer.	Cells	were	
then	 permeabilized	 with	 0.3%	 Triton	 X‐100	 for	 1	hour	 and	 then	
blocked	with	10%	normal	goat	serum	in	PBS	with	0.3%	Triton	X‐100	
for 4 hours at room temperature. Primary antibodies used for over‐
night	incubation	were	anti‐occludin	(1:1000)	and	anti‐ZO1	(1:5000).	
Secondary	antibodies	Alexa	Fluor	488	 (1:500)	and	Alexa	Fluor	594	
(1:500) from Molecular Probes (Life Technologies) were used for in‐
cubation for 2 hour.
2.10 | Statistical analysis
To examine the VMR in response to CRD pressures, the EMG ampli‐
tudes,	 represented	by	calculating	the	AUC,	were	normalized	as	per‐
centage of baseline response for the highest pressure (60 mm Hg) for 
each rat and then averaged for each group of rats. The effects of stress 
and/or	 lubiprostone	 treatment	 on	 the	 VMR	 to	 CRD	were	 analyzed	
using	a	repeated‐measures	two‐way	ANOVA	followed	by	Bonferroni	
posttest comparisons. Unpaired Student’s t test was used to exam‐
ine the data for protein, TEER, FITC‐dextran, and ChIP assays. Results 
were expressed as means ± SEM P < 0.05 was considered statistically 
significant.
3  | RESULTS
3.1 | Lubiprostone prevented chronic stress‐induced 
visceral hyperalgesia in the rat
In	our	previous	studies,	we	demonstrated	that	chronic	WA	stress	 in‐
duced visceral hyperalgesia which was largely blocked by GR receptor 
antagonist	RU‐486.27,35 It is unknown whether lubiprostone will have a 
preventative effect on chronic stress‐associated visceral pain percep‐
tion. In this study, we measured body weight gain, fecal pellet output 
and	visceral	pain	in	WA‐stressed	rats	treated	with	lubiprostone	or	MCT	
vehicle.	Intermittent	10‐day	WA	stress	induced	a	significant	reduction	
in	 body	weight	 gain	 in	MCT‐WA	stress	 rats	 (29.0	±	2.2	g)	 during	 this	
10‐day	stress	period	compared	to	MCT‐CT	rats	(43.5	±	2.8	g)	as	shown	
in	 Figure	 1A	 (P	<	0.001;	 n	=	6‐8).	 Lubiprostone	 treatment	 prevented	
stress‐induced reduction in body weight gain. The average number 
of	 fecal	 pellet	 output	 during	 1‐hour	 stress	 each	 day	was	 0.78	±	0.19	
in	MCT‐CT	rats,	and	it	significantly	increased	to	4.1	±	0.3	in	MCT‐WA	
rats (P < 0.001). Lubiprostone treatment did not affect the fecal pellet 
output	compared	to	MCT‐WA	rats	(Figure	1B).	In	MCT‐WA	rats,	VMR	
in response to CRD, expressed as EMG activity, increased significantly 
to	111.6%	±	13.8%	from	the	control	level	(64.9%	±	11.9%)	of	MCT‐CT	
rats at 40 mm Hg pressure (P	<	0.01;	n	=	6‐8)	and	244.3%	±	23.5%	from	
the	MCT‐CT	 level	 (100.0%	±	9.2%)	 at	60	mm	Hg	pressure	 (P < 0.001; 
n	=	6‐8),	respectively.	In	WA+Lub	rats,	VMR	was	significantly	decreased	
to	72.8%	±	7.3%	and	155.6%	±	38.7%	at	the	distention	pressures	of	40	
and	60	mm	Hg,	 respectively,	when	compared	to	MCT‐WA	rat	groups	
(P < 0.05). No differences in VMR to 10 and 20 mm Hg distention pres‐
sures were observed in these three animal groups (Figure 1C). MCT 
vehicle did not significantly influence VMR to CRD at any distention 
pressure when EMG amplitudes were compared between MCT‐CT rats 
and healthy control rats without any treatment (data not shown).
3.2 | Lubiprostone blocked chronic stress‐induced 
alterations of intestinal epithelial tight junction 
proteins in the rat colon
To test whether lubiprostone treatment affects intestinal epithelial 
tight junctions in chronic stress, we performed quantitative PCR and 
immunoblot	using	the	acutely	harvested	rat	colon	crypts.	As	shown	
in	Figure	2A,	chronic	WA	stress	significantly	decreased	mRNA	lev‐
els of claudin‐1, occludin, and GR receptor in the colon crypts in 
MCT‐WA	rats	compared	to	MCT‐CT	rats	 (P < 0.05), while claudin‐2 
mRNA	was	significantly	increased	(P < 0.05). Lubiprostone treatment 
during	 the	 stress	 phase	 significantly	 increased	mRNA	 levels	 of	 oc‐
cludin	and	claudin‐2	in	this	WA+Lub	rat	group	compared	to	MCT‐WA	
rats (P < 0.01), to the similar levels of MCT‐CT rats, whereas it had 
modest effects on claudin‐1 and GR receptor. Furthermore, Western 
blot	showed	that	WA	stress	induced	49.0%	±	11.9%	decrease	in	clau‐
din‐1 (P	<	0.05),	 73.8%	±	5.8%	 decrease	 in	 occludin	 (P < 0.01), and 
37.2%	±	6.3%	increase	in	claudin‐2	protein	(P	<	0.05)	in	the	MCT‐WA	
rat colon crypts compared to MCT‐CT rats, respectively. Treatment 
with lubiprostone significantly prevented the decreases of occludin 
but not claudin‐1 and increase of claudin‐2 protein in the rat colon. 
The	levels	of	occludin	and	claudin‐2	in	colon	crypts	in	WA+Lub	rats	
were	reversed	to	84.3%	±	5.1%	(P	<	0.05)	and	61.9%	±	6.5%	(P < 0.01) 
of	 their	 corresponding	 levels	 (100%)	 of	MCT‐CT	 rats,	 respectively,	
after lubiprostone treatment as shown in Figure 2B,C. Consistent 
with the quantitative PCR result for claudin‐1, lubiprostone had a 
modest reversal effect on chronic stress‐induced down‐regulation of 
claudin‐1.
F I G U R E  1  Effect	of	lubiprostone	(Lub)	on	chronic	WA	stress‐
induced	visceral	hyperalgesia	in	the	rat.	A,	Body	weight	gain	after	
10‐day	WA	or	SHAM	stress	in	rats	treated	with	lubiprostone	or	MCT	
vehicle.	B,	Averaged	number	of	fecal	pellet	output	during	1	hour	
WA	or	SHAM	stress	period	in	MCT‐CT,	MCT‐WA,	and	WA+Lub	rat	
group.	C,	EMG	amplitude,	expressed	as	AUC	of	the	VMR	to	CRD,	was	
significantly	increased	following	10‐day	WA	stress	compared	with	
the	controls.	Lubiprostone	treatment	largely	prevented	WA	stress‐
induced increase in VMR to CRD at 40 and 60 mm Hg pressures. 
Data	are	expressed	as	mean	±	SEM,	n	=	6‐8	in	each	group.	**P < 0.01; 
***P	<	0.001	for	MCT‐WA	rats	compared	to	the	MCT‐CT	rats.	
#P	<	0.05	for	lubiprostone‐treated	stressed	rats	(WA+Lub)	compared	
to	MCT‐WA	rats	without	lubiprostone	treatment.
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3.3 | Effects of lubiprostone on cortisol‐induced 
changes in tight junctions in human colon crypts and 
Caco‐2/BBE cells
To test whether disruption of tight junctions observed in chronically 
stressed rats can be reproduced in human cells, differentiated Caco‐2/
BBE cells and human colon crypts derived from healthy controls were 
treated with cortisol. The optimal dose for cortisol treatment was 
determined by treating cells with serial concentrations of cortisol for 
24	hours.	As	shown	in	Figure	3A,	occludin	protein	decreased	in	a	dose‐
dependent manner in these cells after cortisol treatment and the dose 
of	500	nmol/L	cortisol	was	used	for	the	subsequent	experiments.	As	
shown	in	Figure	3B,C,	cortisol	treatment	induced	53.8%	±	7.5%	decrease	
in claudin‐1 (P	<	0.05),	45.5%	±	9.4%	decrease	in	occludin	(P < 0.05), and 
171.3%	±	24.3%	 increase	 in	 claudin‐2	 (P < 0.01) compared with the 
control groups, respectively, in differentiated Caco‐2/BBE cells after 
cortisol treatment. Lubiprostone significantly prevented these changes 
caused by cortisol. The protein levels of claudin‐1, occludin, and clau‐
din‐2	were	125.5%	±	9.3%,	92.0%	±	5.3%,	and	191.3%	±	32.9%,	respec‐
tively, in cortisol‐treated cells in the presence of lubiprostone compared 
to their corresponding control levels. The differences between cor‐
tisol‐treated cells with and without lubiprostone were significant 
(P	<	0.05).	As	shown	in	Figure	3D,E,	human	colon	crypts	demonstrated	
55.7%	±	4.4%	decrease	in	claudin‐1	(P	<	0.01),	33.7%	±	9.9%	decrease	in	
occludin (P	<	0.05),	and	70.7%	±	13.5%	increase	in	claudin‐2	(P < 0.01), 
respectively, after cortisol treatment compared with the control groups. 
Co‐treatment with lubiprostone significantly prevented the decreases 
of claudin‐1 and occludin and the increase of claudin‐2. The levels of 
claudin‐1, occludin, and claudin‐2 in lubiprostone and cortisol treated 
were	73.8%	±	13.1%,	81.4%	±	7.04%,	and	147.1%	±	8.6%	of	 their	 cor‐
responding control levels, respectively (P < 0.05).
3.4 | Effects of lubiprostone on paracellular 
permeability in Caco‐2/BBE cells
In differentiated Caco‐2/BBE cell monolayers, TEER was meas‐
ured before and after treatment with cortisol in the presence and 
absence of lubiprostone, while FITC‐dextran leakiness was meas‐
ured	after	cortisol	treatment	with/without	lubiprostone.	As	shown	
in	 Figure	 4A,	 change	 of	 TEER	 decreased	 24.9	±	5.9		ohms/cm2 in 
Caco‐2/BBE monolayers after cortisol treatment for 24 hours, 
whereas	 it	 increased	 14.8	±	7.1		ohms/cm2 in the vehicle con‐
trols. The difference between these two groups was significant 
(P	<	0.01;	n	=	18).	In	the	presence	of	lubiprostone,	change	of	TEER	
increased	28.4	±	9.4		ohms/cm2 in cortisol‐treated cells, which was 
significantly different compared to those without lubiprostone 
co‐treatment (P	<	0.001;	 n	=	18).	 Moreover,	 FITC‐dextran	 meas‐
urement in the differentiated Caco‐2/BBE monolayers showed 
40.7%	±	2.5%	increase	in	the	intensity	of	4	kDa	FITC‐dextran	in	the	
lower chamber of the Transwell cell cultures compared to the con‐
trols (P < 0.01; n = 12). This enhancement was reduced significantly 
to	 122.7%	±	4.8%	 of	 the	 control	 by	 treatment	 with	 lubiprostone	
(P < 0.01; Figure 4B).
3.5 | Lubiprostone prevented cortisol‐induced 
down‐regulation of GR in human samples
We reported previously that GR was down‐regulated after 
cortisol treatment in Caco‐2/BBE cells.34 Here, we examined 
F I G U R E  2   Lubiprostone treatment differentially altered epithelial 
tight	junction	protein	expression	in	the	rat	colon	in	chronic	stress.	A,	
Quantitative PCR analysis of the expression levels of tight junction 
genes including claudin‐1, claudin‐2, and occludin and the expression 
of	GR	receptor	in	colon	crypts	of	MCT‐WA	rats	compared	to	MCT‐
CT rats in the presence and absence of lubiprostone. B, Immunoblot 
for detection of claudin‐1, claudin‐2, and occludin proteins in the 
colon	crypts	in	MCT‐CT,	MCT‐WA,	and	WA+Lub	rats.	C,	Bar	graph	
depicting the relative protein levels of claudin‐1, claudin‐2, and 
occludin	in	WA+Lub	rats	compared	to	MCT‐WA	rats	and	MCT‐CT	
rats.	n	=	4‐6	of	each	group.	*P	<	0.05;	**P	<	0.01	for	MCT‐WA	rats	
compared to MCT‐CT rats. #P < 0.05; ##P	<	0.01	for	WA+Lub	rats	
compared	to	MCT‐WA	rats	without	lubiprostone	treatment.
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whether	 lubiprostone	 treatment	 altered	 GR	 expression.	 As	
shown	 in	 Figure	 5A,	 the	 protein	 level	 of	 GR	 in	 differentiated	
Caco‐2/BBE	 cells	 was	 significantly	 decreased	 to	 36.6%	±	4.7%	
after cortisol treatment for 24 hours (P	<	0.01).	 Administration	
of lubiprostone during cortisol treatment reversed GR expres‐
sion	to	52.6%	±	7.5%	of	the	untreated	level	(P < 0.05). Similarly, 
GR	 protein	 expression	 decreased	 64.1%	±	5.3%	 in	 acutely	 har‐
vested human colon crypts after cortisol treatment for 24 hours 
(P < 0.01) as shown in Figure 5B. Lubiprostone significantly 
reversed	 GR	 protein	 level	 to	 113.5%	±	10.9%	 of	 the	 untreated	
control (P < 0.01). In addition, we examined GR protein levels in 
colon	crypts	from	rats	subjected	to	10‐day	WA	stress	with/with‐
out	lubiprostone.	As	shown	in	Figure	5C,	GR	protein	was	signifi‐
cantly	decreased	 in	 colon	 crypts	 in	MCT‐WA	 rats	 compared	 to	
MCT‐CT rats (P < 0.001; n = 5). Lubiprostone treatment partially 
reserved	GR	protein	 level	 (to	70.6%	±	21.5%)	 in	WA+Lub	group	
compared	 to	 the	 level	 of	 40.1%	±	14.4%	 in	 MCT‐WA	 group.	
The difference between these two groups was not significant 
(P = 0.137; n = 5).
3.6 | Lubiprostone reversed cortisol‐induced down‐
regulation of GR co‐chaperones
We examined GR chaperon proteins in differentiated Caco‐2/BBE 
cells to test the hypothesis that GR function can be regulated by 
lubiprostone.	As	shown	in	Figure	6,	both	cortisol	and	lubiprostone	
did not alter the levels of GR chaperon proteins Hsp90 and Hsp70. In 
contrast, GR co‐chaperon proteins p23 and FKBP5 were significantly 
decreased	to	40.7%	±	6.6%	(P	<	0.01)	and	79.8%	±	10.5%	(P < 0.05) 
of the control levels, respectively, in Caco‐2 cells treated by cortisol. 
Lubiprostone co‐treatment significantly blocked cortisol‐induced 
down‐regulation of p23 and FKBP5, suggesting the regulatory ef‐
fect of lubiprostone on GR expression and function.
3.7 | Lubiprostone inhibited cortisol‐induced 
decrease in GR binding to occludin gene promoter
Next, we tested whether the binding of GR, as a positive transcrip‐
tion factor, to occludin promoter regions was affected by cortisol and 
F I G U R E  3   Differential effects of cortisol and lubiprostone on tight junction proteins in differentiated Caco‐2/BBE cells and acutely 
harvested	human	colon	crypts.	A,	Dose	response	effect	of	cortisol	treatment	(0‐1000	nmol/L;	24	hours)	on	occludin	expression	in	Caco‐2/
BBE cells. B, Differential changes of claudin‐1, claudin‐2, and occludin in Caco‐2/BBE cells treated by 500 nmol/L cortisol for 24 hours in the 
presence and absence of lubiprostone (100 nmol/L). C, Statistical analysis of tight junction protein levels in Caco‐2/BBE cells after cortisol 
and lubiprostone treatment. D, Immunoblots for tight junction proteins in acutely harvested colon crypts from healthy control patients 
after treatment with cortisol (500 nmol/L) and/or lubiprostone (100 nmol/L) for 24 hours. E, Statistical analysis showed differential effects 
of cortisol on claudin‐1, claudin‐2 and occludin protein expression in human colon crypts with/without lubiprostone treatment. n = 3‐4. 
*P	<	0.05;	**P < 0.01 for cortisol treatment compared to the controls. #P < 0.05; ##P < 0.01 for cortisol and lubiprostone‐treated cells 
compared to the cortisol‐treated cells.
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lubiprostone.	As	shown	 in	Figure	7A,	ChIP	analysis	 revealed	that	 the	
binding of GR protein to occludin gene promoter region was decreased 
in	colon	crypts	in	MCT‐WA	rats	compared	to	MCT‐CT	rats.	Treatment	
with lubiprostone during the stress phase prevented the decrease of 
GR binding to the occludin promoter, which is consistent with the ef‐
fect of lubiprostone on chronic stress‐induced down‐regulation of oc‐
cludin protein expression in the rat colon. In differentiated Caco‐2/BBE 
cells, the relative amount of GR binding to occludin promoter decreased 
substantially treated by cortisol compared with controls. Lubiprostone 
treatment prevented the decrease of GR binding to the occludin pro‐
moter caused by cortisol administration as shown in Figure 7B.
3.8 | Lubiprostone prevented corticosterone‐
induced alterations of GR chaperon protein in the rat 
colonic cells
In	 rat	 colonic	 FRC/TEX	 cells,	 occludin	 expression	 and	 localization	
were significantly disrupted after corticosterone treatment and this 
change	was	prevented	by	lubiprostone	treatment	(Figure	8A).	In	con‐
trast,	ZO‐1	expression	and	localization	were	not	altered	by	cortisol	
treatment.	As	shown	in	Figure	8B,	GR	protein	level	was	decreased	
in corticosterone‐treated FRC/TEX cells which was largely reversed 
by lubiprostone, whereas MR was not affected by corticosterone. 
Corticosterone had no significant effect on GR chaperon protein 
Hsp90, but decreased protein levels of GR co‐chaperon proteins p23 
and	 FKBP5.	 Lubiprostone	 treatment	 normalized	 the	 down‐regula‐
tion of p23 and FKBP5 in these cells.
4  | DISCUSSION
In this study, we revealed a novel role for lubiprostone to amelio‐
rate stress‐induced disruption of intestinal epithelial tight junction 
protein expression and function in the rodent and human colon that 
was associated with regulation of GR receptor expression and func‐
tion.	Our	data	demonstrate	that	lubiprostone	prevents	chronic	WA	
stress‐induced down‐regulation of occludin and up‐regulation of 
claudin‐2 in rat colon crypts and significantly reduced visceral hy‐
peralgesia observed in the stressed rats. Stress‐induced alterations 
of claudin‐1, claudin‐2, and occludin were reproduced in Caco‐2/
BBE cells and control human colon crypts treated with cortisol, an 
agonist for GR receptor. Lubiprostone blocked these changes and 
prevented cortisol‐induced epithelial barrier dysfunction in Caco‐2/
BBE monolayers. Furthermore, GR expression was decreased in cor‐
tisol‐treated Caco‐2/BBE cells and human colon crypts, which was 
largely reversed by lubiprostone. ChIP‐qPCR assay revealed that 
lubiprostone	normalized	decreased	GR	binding	at	occludin	promoter	
region under stress conditions. In addition, GR and its co‐chaperone 
proteins p23 and FKBP5 were down‐regulated after corticoster‐
one treatment in rat colonic cells and lubiprostone prevented these 
changes.
Intestinal epithelial tight junction protein claudins have two dif‐
ferent functional subcategories affecting paracellular permeability. 
One type of claudins, such as claudin‐1, acts as “sealing” molecules 
which tighten the paracellular pathway against ions and larger sol‐
utes and maintain the integrity of the paracellular tight junctions with 
other tight junction proteins, that is, occludin. Disruption of these 
claudins and occludin expression decreases transepithelial electric 
resistance (TEER) and increases paracellular permeability. The other 
type of claudins, such as claudin‐2, function as “pore‐forming” mol‐
ecules which enhance paracellular permeability in a charge‐selec‐
tive fashion.36,37 For example, claudin‐1 contributes to maintaining 
a high TEER in cell culture models and is indispensable for creating 
and maintaining the epidermal barrier.38,39 In contrast, over‐expres‐
sion of claudin‐2 induces lower transepithelial resistance in kidney 
cells and increases paracellular permeability.40,41 In our study, we 
observed	that	chronic	WA	stress	induced	the	reduction	in	the	pro‐
tein levels of claudin‐1 and occludin and increase in the protein level 
of claudin‐2 in colonic epithelium in rats. This is consistent with our 
previous report that corticosterone induced down‐regulation of 
tight junction proteins and increase in colon epithelial permeability 
FI G U R E 4 Paracellular permeability measurements in differentiated 
Caco‐2/BBE monolayers in the presence and absence of cortisol and 
lubiprostone.	A,	The	changes	of	transepithelial	electrical	resistance	
(TEER) before and after treatment with cortisol (500 nmol/L) and/or 
lubiprostone (100 nmol/L) for 24 hours in Caco‐2/BBE cells cultured 
in	Transwells	for	21	days.	n	=	18.	(B)	FITC‐dextran	(4	kDa)	permeability	
measurement in 21‐day cultured Caco‐2/BBE cells after 500 nmol/L 
cortisol treatment for 24 hours in the presence and absence of 
lubiprostone	(100	nmol/L).	n	=	12.	**P < 0.01 for cortisol‐treated cells 
compared to the controls. #P < 0.05; ###P < 0.001 for cortisol and 
lubiprostone‐treated cells compared to the cortisol‐treated cells.
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in the rats9 and that chronic stress resulted in impairment of intes‐
tinal barrier function and visceral hyperalgesia.9,10 It has been re‐
ported that claudin‐2, which is sensitive to stressful conditions, is 
involved	in	paracellular	water	transport	and	contributes	23%‐30%	of	
the total water transport in proximal kidney tubules.42,43 The expres‐
sion of pore‐forming claudin‐2 could be induced by tumor necrosis 
factor‐neuropeptide Y “cross‐talk” in vitro which was associated 
with increased epithelial permeability in inflammation.44 In normal 
colon, claudin‐2 is highly expressed in the crypt bottom containing 
the undifferentiated and proliferative colonocytes.45 However, the 
detailed function of claudin‐2 in the colon is largely unknown, partic‐
ularly	under	chronic	stress	conditions.	We	hypothesize	that	chronic	
stress‐induced up‐regulation of claudin‐2 in the colon can lead to 
increased water secretion and epithelial permeability and that pre‐
vention	of	claudin‐2	increase	by	lubiprostone	can	normalize	chronic	
stress‐induced disruption of intestinal barrier function. It has been 
F I G U R E  5   Effects of lubiprostone 
on GR receptor protein expression in 
differentiated Caco‐2/BBE cells, human 
colon	crypts,	and	stressed	rats.	A,	Protein	
expression of GR receptor in 21‐day 
cultured Caco‐2/BBE cells treated by 
cortisol (500 nmol/L) and lubiprostone 
(100 nmol/L) for 24 hours. B, Cortisol 
treatment (500 nmol/L; 24 hours) 
significantly decreased GR protein level 
in human colon crypts. Lubiprostone 
(100 nmol/L) prevented cortisol‐induced 
down‐regulation of GR receptor. C, GR 
protein expression in colon crypts isolated 
from	MCT‐CT,	MCT‐WA,	and	WA+Lub	rat	
groups.	n	=	3‐5.	**P < 0.01 for cortisol‐
treated group compared to the controls. 
***P	<	0.01	for	MCT‐WA	rats	compared	
to MCT‐CT rats. #P < 0.05; ##P < 0.01 for 
cortisol and lubiprostone‐treated group 
compared to the cortisol‐treated group.
F I G U R E  6   Differential effects of cortisol and lubiprostone on the alterations of GR chaperone proteins in differentiated Caco‐2/BBE 
cells.	A,	Immunoblots	for	probing	the	express	levels	of	GR	chaperone	and	co‐chaperone	proteins	including	Hsp90,	Hsp70,	p23,	and	FKBP5	in	
21‐day cultured Caco‐2/BBE cells in the presence and absence of cortisol (500 nmol/L; 24 hours) and lubiprostone (100 nmol/L; 24 hours). 
B, Statistical bar graph showed that cortisol treatment decreased p23 and FKBP5 in Caco‐2/BBE cells and lubiprostone treatment largely 
blocked	down‐regulation	of	p23	and	FKBP5	induced	by	cortisol.	n	=	3.	*P	<	0.05;	**P < 0.01 for cortisol‐treated cells compared to the 
controls. #P < 0.05; ##P < 0.01 for cortisol and lubiprostone‐treated group compared to the cortisol‐treated group.
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reported that claudin‐2 is increased in the jejunum in IBS with diar‐
rhea,46 supporting an important role of this tight junction protein in 
regulation of intestinal barrier function.
In our previous study, we observed significant decrease in GR 
receptor expression in colon epithelial cells in the stressed and cor‐
ticosterone‐treated rats, which was largely blocked by corticoid re‐
ceptor	antagonist	RU‐486.9 In this study, we further demonstrated 
that GR protein was down‐regulated in differentiated Caco‐2/BBE 
cells and normal human colon crypts after cortisol treatment that 
was associated with increased paracellular permeability, suggesting 
a role for GR in modulation of tight junction protein expression and 
function. These results are consistent with other studies using in 
vitro cell lines.47,48 Our ChIP‐qPCR analysis showed that GR could di‐
rectly bind to occludin promoter and this GR binding was decreased 
in	the	colon	crypts	 in	WA‐stressed	rats,	 indicating	a	direct	regula‐
tory role of GR, as a positive transcription factor, for occludin tran‐
scription and expression. Restoration of GR protein by lubiprostone 
thus reserved the decrease in GR transcriptional binding to occludin 
promoter induced by chronic stress, increased occludin transcription 
and	expression,	and	subsequently	normalized	paracellular	permea‐
bility. Similar regulatory role of GR for claudin‐1 was reported in our 
recent study.34 Interestingly, chronic stress‐induced decrease in GR 
expression was prevented by lubiprostone in Caco‐2/BBE cells and 
human	colon	crypts,	but	not	in	chronic	WA	stress	rat	model	which	
showed a modest effect. One possible explanation is the complexity 
of in vivo rat stress model compared to the relatively simple in vitro 
model	 using	 cultured	 cells/crypts.	 Adrenocorticotropic	 hormone,	
at systemic level, and several neuropeptides, at local level, can be 
released in the animal model under chronic stress conditions, which 
may modulate GR transcriptional binding to occludin and claudin‐1 
promoter regions in the presence of lubiprostone. Secondly, we ob‐
served large variability in down‐regulation of GR protein in stressed 
rats and in stressed rats treated with lubiprostone. The difference 
in baseline levels of GR receptor, tight junction proteins, and their 
epigenetic	regulatory	status	in	healthy	control	rats,	 including	DNA	
methylation in gene promoter regions, may contribute to the differ‐
ential effects observed in animals subjected to chronic stress and 
lubiprostone treatment. Further studies are needed to dissect the 
detailed regulatory pathways in stress axis that are involved in regu‐
lation of differential restoration of disrupted epithelial tight junction 
proteins by lubiprostone.
Like many signaling proteins, the function of GR depends on 
the coordination of Hsp90 and Hsp70 chaperone cycles. Full recov‐
ery	of	ligand	binding	to	GR	requires	ATP	hydrolysis	on	Hsp90	and	
the Hop and p23 co‐chaperones.15 In our study, both Hsp90 and 
Hsp70 were not affected by GR agonist, cortisol/corticosterone, 
in Caco‐2/BBE and FRC/TEX cells. However, p23 expression was 
significantly down‐regulated in the colon epithelial cells in stressed 
rats and colonic cell lines treated with glucocorticoids, suggesting 
the recovery of GR ligand binding was significantly incapacitated 
under chronic stress conditions. In addition, FKBP5, a Hsp90 co‐
chaperone that regulates GR function,49 was decreased in gluco‐
corticoid‐treated colonic cells. This result is consistent with the 
F I G U R E  7   Chromatin immunoprecipitation (ChIP) followed 
by PCR analysis for transcription factor GR binding to occludin 
promoter regions in rat colon crypts and differentiated Caco‐2/
BBE	cells.	A,	ChIP	using	anti‐GR	antibody	followed	by	PCR	for	
occludin	promoter	in	colon	crypts	isolated	from	MCT‐CT,	MCT‐WA,	
WA+Lub	rats.	PCR	neg:	no	input	DNA;	ChIP	neg:	ChIP	with	normal	
rabbit	IgG.	Input:	4%	input	DNA	from	relevant	rat	crypt	samples	for	
normalization.	B,	ChIP	and	PCR	analysis	of	GR	binding	to	occludin	
promoter region in differentiated Caco‐2/BBE cells treated by 
cortisol (500 nmol/L) for 24 hours in the presence and absence of 
lubiprostone (100 nmol/L)
F I G U R E  8   Effects of corticosterone (CORT) and lubiprostone 
on occludin, GR, and GR chaperone proteins in rat colonic FRC/
TEX	cells.	A,	Immunofluorescence	for	occludin	and	ZO‐1	expression	
in FRC/TEX cells treated by corticosterone (500 nmol/L) for 
24 hours in the presence and absence of lubiprostone (100 nmol/L). 
The	expression	and	localization	of	occludin	but	not	ZO‐1	was	
significantly disrupted in corticosterone‐treated cells compared 
to the controls. Lubiprostone largely reversed this change. B, 
Immunoblots for GR, MR, and GR chaperone proteins Hsp90, p23, 
and FKBP5 in 500 nmol/L corticosterone‐treated FRC/TEX cells for 
24 hours with/without lubiprostone (100 nmol/L). n = 3 
     |  11 of 13ZONG et al.
previous report that FKBP5 links to the development of posttrau‐
matic stress disorder (PTSD) and was found to be less expressed 
in PTSD.50 These data strongly support a function of FKBP5 as a 
modulator of the response to stressful life events. It is very likely 
that FKBP5 functions in chronic stress through its action in GR 
resistance and translocation.17	Accordingly,	down‐regulation	of	GR	
altered the transcription and expression of epithelial tight junction 
proteins and disrupted barrier function under chronic stress con‐
ditions and subsequently induced visceral hyperalgesia in stressed 
animals. However, the exact mechanism underlying how these 
co‐chaperones modulate GR ligand binding and translocation to 
the nucleus in colon epithelial cells in chronic stress remains to be 
elucidated.
It has been reported that lubiprostone significantly im‐
proves symptoms in patients with chronic constipation51 and 
is more effective than placebo in improving abdominal pain or 
bloating in IBS patients with constipation.52 The signal trans‐
duction pathway includes activation of CIC‐2 channels resulting 
in a chloride‐rich fluid secretion, activation of prostaglandin E 
type receptors with increase in mucus/fluid secretion, and res‐
titution of epithelial cell barrier properties.26,28,51 The current 
study demonstrates that lubiprostone significantly reduced 
chronic stress‐induced visceral hyperalgesia in the rat, which 
is consistent with the effects reported in IBS patients.52 This 
beneficial effect of lubiprostone most likely contributes to 
the prevention of chronic stress‐induced changes in epithelial 
tight junction proteins including claudin‐1, claudin‐2, and oc‐
cludin, and subsequent recovery of paracellular permeability in 
both in vivo and in vitro models. Importantly, our study further 
demonstrated a novel role for lubiprostone to regulate epithelial 
barrier function through modulation of GR expression and func‐
tion. Lubiprostone significantly prevented down‐regulated of 
GR co‐chaperones including p23 and FKBP5 induced by chronic 
stress, suggesting a signaling modulation through GR ligand 
binding recovery and nucleus translocation. The prevention of 
down‐regulation in GR results in reconstitution of GR binding 
to tight junction gene promoter regions and increases epithelial 
cell tight junction gene transcription, protein expression, and 
thereby restores epithelial cell barrier integrity and function. 
On the other hand, heat‐shock proteins have been reported to 
regulate chloride channel expression and function.53 Recovery 
of p23 and FKBP5 by lubiprostone may, therefore, lead to en‐
hancement of chloride channel activity and fluid secretion to 
reduce chronic stress‐induced symptoms. In our study, we can‐
not exclude the possibility that lubiprostone may also directly 
activate CIC‐2 chloride channels25,54 since lubiprostone was 
gavage‐delivered in rat models and administrated in the inner 
chamber of transwell cultures of Caco‐2 cells. However, the fact 
that lubiprostone does not affect fecal pellet output in stressed 
rats does not support the involvement of direct activation of 
CIC‐2 channels in this animal model. It is noteworthy that GR 
co‐chaperone p23 is also identified as prostaglandin E synthase 
3, a cytosolic prostaglandin E2 synthase. The recovery of the 
expression and function of this prostaglandin E synthase may 
increase the production of prostaglandin E2, activate prosta‐
glandin EP receptors, and downstream signaling pathways that 
promote intestinal epithelial restoration.55
In summary, our results support the novel concept that 
lubiprostone has a protective role in chronic stress‐induced 
impairment in intestinal epithelial cell tight junction protein 
expression and function resulting in visceral hyperalgesia. 
These actions of lubiprostone appear to be attributable to the 
prevention of stress‐induced disruption of intestinal epithelial 
tight junction protein expression and maintenance of intesti‐
nal barrier function associated with modulation of GR receptor 
expression and function. GR, acting as a positive transcription 
factor for claudin‐1 and occludin, regulates tight junction gene 
transcription and expression. Chronic stress‐induced down‐
regulation of GR receptor, therefore, leads to GR‐mediated de‐
creases in tight junction proteins claudin‐1 and occludin and 
increase in claudin‐2, resulting in increased paracellular per‐
meability in animal models and cell lines. Lubiprostone treat‐
ment significantly prevents stress‐induced down‐regulation of 
GR receptor and its chaperone proteins, which promotes the 
recovery of GR‐mediated regulation of tight junction protein 
expression, paracellular permeability, and visceral pain percep‐
tion. These observations may help guide future drug develop‐
ment in this area by providing a rationale to target pathways 
that either prevent impairment and/or promote restoration in 
intestinal epithelial cell tight junction protein expression and 
function.
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